 SEATTLE, March 31, 2021 PRNewswire -- CTI BioPharma Corp. Nasdaq: CTIC CTI, a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers, today announced that it intends to offer and sell shares of its common stock and series X1 preferred stock the Series X1 Preferred in an underwritten registered public offering. All of the securities in the proposed offering are to be sold by CTI. 